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Abstract
Background:  The role of basic fibroblast growth factor (bFGF) in chemoresistance is
controversial; some studies showed a relationship between higher bFGF level and chemoresistance
while other studies showed the opposite finding. The goal of the present study was to quantify
bFGF levels in archived tumor tissues, and to determine its relationship with chemosensitivity.
Methods:  We established an image analysis-based method to quantify and convert the
immunostaining intensity of intra-tumor bFGF to concentrations; this was accomplished by
generating standard curves using human xenograft tumors as the renewable tissue source for
simultaneous image analysis and ELISA. The relationships between bFGF concentrations and tumor
chemosensitivity of patient tumors (n = 87) to paclitaxel were evaluated using linear regression
analysis.
Results: The image analysis results were compared to our previous results obtained using a
conventional, semi-quantitative visual scoring method. While both analyses indicated an inverse
relationship between bFGF level and tumor sensitivity to paclitaxel, the image analysis method, by
providing bFGF levels in individual tumors and therefore more data points (87 numerical values as
opposed to four groups of staining intensities), further enabled the quantitative analysis of the
relationship in subgroups of tumors with different pathobiological properties. The results show
significant correlation between bFGF level and tumor sensitivity to the antiproliferation effect, but
not the apoptotic effect, of paclitaxel. We further found stronger correlations of bFGF level and
paclitaxel sensitivity in four tumor subgroups (high stage, positive p53 staining, negative aFGF
staining, containing higher-than-median bFGF level), compared to all other groups. These findings
suggest that the relationship between intra-tumoral bFGF level and paclitaxel sensitivity was
context-dependent, which may explain the previous contradictory findings on the merit of using
plasma or urine bFGF level as a prognostic indicator.
Conclusion: The present study established a quantitative image analysis method that enabled the
measurement of intratumoral bFGF level in archived tissues. The ability to quantify a potential
biomarker provided the opportunity to study the relationship between the biomarker and
chemosensitivity in tumor subgroups and thereby enabled hypothesis generation for additional
translational research.
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Background
A conventional paradigm in cancer drug development is
to identify worthy molecular targets and the correspond-
ing intervening agents in preclinical models, followed by
clinical evaluations in human patients. With a few excep-
tions, the clinical development was done without the
knowledge whether the intended targets were present or
important for the patients enrolled in clinical trials. This
generalist approach has not been highly productive. For
example, from 1996 through 2002, 209 anticancer drugs
or treatments aiming at 18 newly identified molecular tar-
gets (e.g., growth factors, angiogenesis, DNA structure
modifications, extracellular matrix proteins, apoptosis-
regulatory proteins) entered clinical evaluation, and only
12 drugs/treatments or less than 6% produced survival
benefits [1].
An emerging paradigm of matching molecular targeted
therapy with patients or diseases with the intended targets
has yielded some successes. The most astounding example
is imatinib, which has shown significant activity in
chronic myelogenous leukemia and gastrointestinal stro-
mal tumor, the two diseases that have the two intended
targets of imatinib (Bcr-Abl tyrosine kinase and c-Kit tyro-
sine kinase) as the respective key lesions [2,3]. On the
other hand, most human cancers have multiple lesions in
multiple signaling pathways and would be less likely to
respond to a single agent targeting a single aspect in the
faulty pathways. A more likely scenario is where the
intended molecular target can be readily identified and
used to preselect patients for evaluation. An example of
success in this area is trastuzumab, a humanized mono-
clonal antibody that binds to the HER2/neu (erbB2)
receptor and thereby prevents signal transduction. In
HER2-positive metastatic breast cancer patients, addition
of trastuzumab to chemotherapy significantly improved
the time to progression, response rate, and overall survival
[4]. Conversely, while gefitinib, an inhibitor of epidermal
growth factor receptor (EGFR) typrosine kianse, improved
the objective response rate in non-small cell lung cancer
patients, it did not produce survival benefits. A subse-
quent study identified several qualitative (EGFR mutation
status) and quantitative markers (number of EGFR gene
copies, EGFR protein level) as potentially important prog-
nostic indicators for response rate and survival [5]. Taken
together, these examples illustrate that successful transla-
tion of molecular discoveries to useful clinical interven-
tions is possible. The gefitinib example further highlights
the potential importance of quantifying the levels of
molecular markers.
Our laboratory is interested in evaluating fibroblast
growth factors (FGF) as potential targets for overcoming
chemoresistance. This is based on our finding that extra-
cellular basic FGF (bFGF) induces broad spectrum chem-
oresistance in cultured rodent and human prostate cancer
cells [6]. This finding is consistent with the findings in
small cell lung cancer cells, bladder cancer cells, chronic
lymphocytic leukemic cells and fibroblasts, where bFGF
causes resistance to multiple chemotherapeutic drugs
including etoposide, cisplatin, fludarabine, doxorubicin,
methotrexate, hydroxyurea, 5-fluorouracil, paclitaxel, N-
(phosphonacetyl)-L-aspartic acid [7-9]. On the other
hand, bFGF has also shown the opposite effect and sensi-
tizes breast, prostate, ovarian and pancreatic cancer cells
to different chemotherapeutic agents including cisplatin,
etoposide, 5-fluorouracil, doxorubicin, carboplatin, and
docetaxel [7]. In cancer patients, the role of bFGF expres-
sion in clinical prognosis is controversial. In pancreatic
cancer, there is no relationship between the intra-tumoral
level of bFGF and postoperative recurrence and survival,
but an increased FGF receptor expression is associated
with shorter survival [10]. A similar observation was made
in non-small cell lung cancer patients [11]. There are also
reports indicating an opposite relationship in patients for
several cancer types. One study showed an association
between increased bFGF expression in tumors and shorter
survival in node-negative breast cancer patients [12],
whereas other studies showed an association between
increased intra-tumoral bFGF expression and better prog-
nosis in breast cancer patients [13-17]. Similar (contradic-
tory) results between bFGF expression and prognosis have
also been reported for ovarian cancer [18] and pediatric
high-grade gliomas [19]. The reasons for the apparently
contradicting relationships between bFGF level and prog-
nosis are not clear.
bFGF is a pleotropic growth factor and its levels is affected
by multiple processes (e.g., during would healing, angio-
genesis). Previous studies on the relationship between
bFGF level and chemosensitivity typically test bFGF levels
in plasma or urine. Analysis of bFGF level in tumors is the-
oretically more likely to correlate with the tumor chemo-
sensitivity, but is limited by the lack of accessibility to
patient tumor samples. Hence, a method that allows the
use of archived tissues may have greater utility, especially
if the evaluation is performed retrospectively for, e.g., the
purpose of preliminary testing whether a laboratory-gen-
erated hypothesis may have clinical utility. A typical
method for studying archived tissues is immunohisto-
chemical staining the protein-of-interest and scoring the
staining intensity by visual examination. We applied this
method to study the relationship, and established an
inverse correlation, between intra-tumoral bFGF level and
tumor sensitivity to paclitaxel in 96 patient tumors [20].
Because the visual examination method is highly depend-
ent on investigator-defined parameters, there is the poten-
tial for unintended bias. Furthermore, the scoring method
primarily describes the outcome in discontinuous terms
(i.e., yes vs no, more vs less), and therefore has limitedJournal of Translational Medicine 2008, 6:4 http://www.translational-medicine.com/content/6/1/4
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utility in situations that require the numerical value of the
biomarker.
The present report described the development of a quan-
titative image analysis-based method to analyze bFGF lev-
els in archived patient tumor tissues. The image analysis
results indicated an inverse relationship between intra-
tumoral bFGF levels and paclitaxel sensitivity, and ena-
bled the identification of four pathobiological parameters
(stage, p53 and aFGF status, higher-than-median bFGF
level) that affected the relationship between bFGF levels
and paclitaxel sensitivity.
Methods
Chemicals and supplies
Bicinchoninic acid and bFGF monoclonal antibody were
purchased from Sigma Chemical Co. (St. Louis, MO),
Streptavidin-Biotin detection kit from Dako (Carpiteria,
CA), cefotaxime sodium from Hoechst-Roussel (Somer-
ville, NJ), DAB (3,3 diaminobenzidine tetrahydrochlo-
ride) substrate kit from BioGenex (San Ramon, CA), and
collagen gel from Ethicon (Somerville, NJ). All other cell
culture supplies were purchased from GIBCO (Grand
Island, NY). All chemicals and reagents were used as
received.
Development of image analysis method
The image analysis-based measurement was accom-
plished in 4 steps: (a) Identified the parameters for image
analysis and developed a macro that automated the pro-
cedures. (b) Identified the human xenografts tumors that
yielded a 100-fold range of bFGF levels as measured by
ELISA. (c) Comparison of bFGF levels in xenograft tumors
measured by image analysis and ELISA, to obtain standard
curves. (d) Using the standard curve to convert the image
analysis readings to protein levels.
Human tumor specimens
Archived tissues of tumors previously studied for paclit-
axel sensitivity were used [20]. Of the original 96 patient
tumors described in the previous study, 87 (15 bladder,
14 breast, 22 head and neck, 13 ovarian, and 23 prostate)
contained sufficient materials for the current study. The
pharmacodynamics of paclitaxel effects in these tumors
were obtained from previous report [20]. The present
study used the control, untreated samples to determine
the baseline bFGF level.
Animal protocols
Establishing standard curves for quantifying the bFGF
level required renewable tumor source. This was accom-
plished by using human xenograft tumors maintained in
immunodeficient mice. We screened several human
tumor cell lines, i.e., prostate (PC3), pancreatic (MiaPaCa-
2 and Hs766T), colon (HT29), ovarian (SKOV3), renal
cell carcinoma (RCC), and pharynx (FaDu) (American
Type Culture Collection, Rockville, MD). Pilot studies
indicated a ~100-fold range in the bFGF levels in these cell
lines. The four cell lines that yielded the greatest dynamic
range of bFGF levels, i.e., FaDu, HT29, PC3, and MiaPaCa-
2, were selected for further studies. Cells were cultured at
37°C in a humidified atmosphere containing 5% CO2, in
culture medium (PC3 and MiaPaCa-2 in DMEM medium,
HT29 in McCoy's 5A plus 0.1% non-essential amino
acids, and FaDu in MEM medium plus amino acids) sup-
plemented with 10% fetal bovine serum, 90 mg/ml gen-
tamicin, 2 mM L-glutamine, and 90 mg/ml cefotaxime.
Five-week old mice were purchased from the National
Cancer Institute (Bethesda, MD), housed and cared for in
accordance with institutional guidelines. Tumors cells
were harvested from sub-confluent cultures using trypsin,
suspended in serum free medium, and implanted subcu-
taneously into the flank on both sides of a mouse (2 × 106
cells/200 µl per injection site). PC3 cells were implanted
in male Balbc/nu.nu mice, HT29 in female athymic nude
mice, and MiaPaCa-2 and FaDu in male athymic nude
mice. Tumors (5–7 mm in length) were harvested and,
after removing the non-tumor tissues, were each divided
into two halves. One-half was fixed in 10% formalin and
embedded in paraffin for immunohistochemical staining
for bFGF and image analysis. The other half was used to
analyze for bFGF level using ELISA.
ELISA analysis of bFGF levels
Xenograft tumors were weighed, minced, and sonicated in
a mixture of ice cold RIPA lysis buffer (containing 150
mM NaCl, 50 mM Tris (pH 7.4), 1% NP-40, 1% deoxy-
cholate, 0.1% sodium dodecyl sulfate, 2 mM EDTA, 50
mM NaF; Upstate Biochem., Lake Placid, NY), 0.2% Pro-
tease Inhibitor Cocktail Set III (CalBiochem, San Diego,
CA), and 1 mM phenylmethylsulfonyl-fluoride. Tumor
lysates were centrifuged at 14,000 rpm for 15 min and the
supernatant was stored at -70°C and subsequently ana-
lyzed for bFGF level using an ELISA kit (Oncogene, Cam-
bridge, MA) according to manufacturer instructions. The
antibody was murine monoclonal anti-bFGF antibody
conjugated to horseradish peroxidase. Detection limit of
the assay was 2.5 pg/ml.
Quantification of FGF levels in tumor tissues using image 
analysis
Sections of xenograft tumors and archived patient tumors
were stained for bFGF using immunohistochemical meth-
ods as previously described, with the exception that we
used only one antibody dilution (1:50) [20,21]. The inter-
day variations in staining intensity were established using
the same standard curve samples stained on different
days; the average variations in the intensity in individualJournal of Translational Medicine 2008, 6:4 http://www.translational-medicine.com/content/6/1/4
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samples (5 repeats) were 28.1% and the average variation
in the resulted standard curve slope was 18.5%.
Images were captured at a magnification of 400× using a
Hamamatsu (Hamamatsu-City, Japan) color chilled
3CCD camera attached to a ZEISS (Thornwood, NY) Axio-
vert 35 microscope, saved in 8-bit TIF format and ana-
lyzed in the HSI format (hue, saturation, intensity). The
HSI format was preferred over the standard RGB format
due to the better separation of the brown (bFGF staining)
and blue (hematoxylin counterstain) colors. A macro was
written in Optimas® (version 6.51, Media Cybernetics, Sil-
ver Spring, MD) to enable unsupervised, high throughput
processing of the images. The macro opened each image
in turn, applied a user defined threshold to distinguish the
brown from the blue staining, extracted the sum of the
optical densities (OD) for each image, and converted the
data to the corresponding bFGF level using a standard
curve.
We quantified 10 images for each of the standard curve
tumor samples, and on average 4 images per patient
tumor (determined by the amount of available tissues).
bFGF standard curve
To correct for day-to-day variations in staining intensity,
the four standard curve xenograft tumor samples were sec-
tioned and processed together with patient tumor sam-
ples. Tumor sections were photographed and the sums of
OD were calculated using the macro. For the xenograft
tumor samples, the image analysis results (sum of OD val-
ues) were plotted against the ELISA results on bFGF levels
in respective tumors, to generate a standard curve.
Statistical analysis
Coefficients of determination (r2) were calculated using
linear regression (SAS Inc., Cary NC, USA). Confidence
intervals around r2 were estimated using Fisher's Z trans-
formation [22].
Results
Development of quantitative image analysis method
Figure 1 shows the bFGF immunostaining in patient
tumors. Consistent with our previous finding [20], the
location of the staining varied substantially within indi-
vidual tumors and between tumors. For example, some
tumors showed staining exclusively in the cytoplasm or
exclusively in the nucleus, whereas some tumors showed
staining in both areas. Substantial variations in the stain-
ing intensity within an individual tumor, as would be
expected due to the heterogeneity in tissues, were also
observed. We analyzed images with varying staining char-
acteristics (e.g., strong and weak staining in cytoplasm
and nucleus, strong and weak staining in stromal tissues)
to identify the dynamic ranges of the HSI parameters
(hue, saturation, and intensity). The threshold values for
the hue and saturation parameters were set to distinguish
the blue stain (for nuclei) from the brown stain (for
bFGF). The threshold value for the intensity parameter
was set by incrementally changing the range such that the
final value found in 20 randomly selected slides (4 from
each tumor type) accurately identified the visually bFGF-
stained areas while excluding the visually non-stained
areas (e.g., cellular debris, blood cells). The selected
threshold values were used for subsequent studies.
We evaluated several quantitative parameters. The use of
gray values (mean value, log grey vale) was ruled out
because the results obtained using this parameter showed
a very narrow range of values and did not correlate with
the ELISA results, e.g., tumors (PC3 and MiaPaCa-2) that
showed a 4-fold difference in bFGF concentration by the
ELISA assay yielded respective gray values of 135 and 129
or a 5% difference. The total area stained for bFGF (posi-
tive vs negative) showed a good correlation with the ELISA
results (r2 = 0.988, p < 0.005). The Average OD value pro-
vided a slightly better correlation (r2 = 0.990, p < 0.005),
but did not provide a value for the non-stained area. In
comparison, the sum of OD captured the differences in
staining intensity and the sum of the positively-stained
areas. For example, HT29 and FaDu tumors showed very
bFGF staining in patient tumors Figure 1
bFGF staining in patient tumors. Surgical tumor specimens from patients (n = 87, untreated) were stained for bFGF as 
described in Materials and Methods. Representative samples of each tumor type are shown. 400× magnification.
Bladder Ovarian Prostate Breast Head and Neck Bladder Ovarian Prostate Breast Head and NeckJournal of Translational Medicine 2008, 6:4 http://www.translational-medicine.com/content/6/1/4
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different bFGF staining patterns, i.e., punctuated, high
intensity staining in HT29 vs diffused and less intense
staining in FaDu (Figure 2A). But these tumors showed
similar sums of OD, in agreement with the similar total
bFGF levels measured by ELISA. Furthermore, the sums of
OD were linearly correlated with the bFGF levels meas-
ured by ELISA, in 4 tumor types (Figure 2B; y = 690.5x; r2
= 0.996, p < 0.001). Subsequent analysis used the sum of
OD parameter.
Figure 2B shows a representative standard curve, covering
the range of 0 to 208 pg bFGF/mg protein. Three of the
four tumors used to obtain the standard curve showed a
narrower bFGF concentration range of 0–60 pg/mg pro-
tein. The highest level of 208 pg/mg was derived from
MiaPaCa-2 tumor. Exclusion of the MiaPaCa-2 tumor did
not significantly alter the r2  value. A majority of the
patient tumor samples (65/87, 75%) used in the present
study showed < 60.0 pg bFGF/mg protein.
Comparison of visual scoring and imaged analysis results
Table 1 compares the results obtained using the compu-
terized image analysis results to our earlier results estab-
lished using the conventional, visual scoring method. For
bFGF levels in individual tumors, the results from the two
methods show a significant, positive correlation (r2  =
0.354, p < 0.0001). For the relationship between bFGF
levels and paclitaxel sensitivity in individual tumors, both
methods yielded significant correlation, but the image
analysis results showed 2–4 times higher r2 values.
Relationship between bFGF level and paclitaxel sensitivity 
in individual patient tumors
Data on tumor sensitivity to the antiproliferation and
apoptotic effects of paclitaxel were obtained from our pre-
vious report [20]. The antiproliferative effects were quan-
tified in terms of the drug concentration required to
produce 30% inhibition of bromodeoxyuridine labeling
index (IC30) and the maximum inhibition of the same
parameter (EMAX). bFGF levels in tumors were signifi-
cantly and inversely correlated with tumor sensitivity to
bFGF standard curve Figure 2
bFGF standard curve. (A) Staining of bFGF (brown color) in PC3, HT29, FaDu, and MiaPaCa-2 tumors. Counter-stained 
with hematoxylin (blue). 400× magnification. The corresponding respective bFGF levels measured using ELISA were 39.0, 57.3, 
60.0, and 208 pg/mg total protein. Negative control: MiaPaCa-2 tumor stained with nonspecific, IgG antibody. (B) bFGF stand-
ard curve (y = 690.5x; r2 = 0.996, p < 0.001). Mean ± Standard deviations.
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the antiproliferation effect of paclitaxel (Figures 3 and 4).
No relationship was observed between bFGF levels and
maximum apoptotic index (data not shown).
Effects of tumor pathobiological parameters on the 
relationship between bFGF level and paclitaxel sensitivity
The tumor pathobiological data of patient tumors were
obtained from our previous report [20]. Analysis of the
relationship between bFGF level and tumor sensitivity to
the antiproliferation effect in tumor subgroups revealed
significantly better correlations (i.e., higher r2 values) in
stage III-IV, p53-positive and aFGF-negative tumors, and
tumors with higher-than-median bFGF level (Figures 3
and 4), compared to low stage (I-II), p53-negative, aFGF-
positive, and low bFGF tumors. The median bFGF level
was 9.8 pg/mg protein. No differences were observed for
the other pathobiological parameters (i.e., high or low
grade, high or low levels of p-glycoprotein or Bcl-2).
Discussion
Biomarkers are gaining importance in the development
and usage of molecular medicines. The present study
presents a computerized image analysis method for quan-
tifying protein biomarkers in archived, paraffin-embed-
ded clinical samples. The two advantages of using
immunohistochemical staining for protein-of-interest are
the availability of archived samples and, because the 3-
dimensional structure is maintained, the spatial or subcel-
lular distribution information that is not available in
methods that use tissue homogenates or extracts (e.g.,
ELISA, Western blotting).
Our image analysis results indicate statistically significant
correlation between bFGF level and the antiproliferation
effect of paclitaxel (measured as EMAX and IC30), but no
relationship between bFGF level and the maximum apop-
totic index. Both findings are consistent with our earlier
findings using the conventional, visual scoring method.
However, while both methods yielded the same finding of
an inverse correlation between bFGF level and tumor sen-
sitivity to the antiproliferation effect of paclitaxel, the
image analysis method provided more robust data and
presented several additional advantages, as follows.
The visual scoring method was semi-quantitative and
based on the differential staining intensity at three differ-
ent antibody concentrations. For example, a tumor show-
ing no staining at the highest antibody concentration was
scored as negative, a tumor showing positive staining at
different antibody concentrations were scored as one, two
or three pluses. In comparison, the current method
required using a single antibody dilution, and, because
the quantitative image analysis results were based on the
results obtained from simultaneously stained standard
curve samples, was not subjected to or affected by inter-
day variability in staining intensity. Furthermore, the
image analysis method applied the same analysis param-
eters to all samples and therefore minimized the potential
operator bias.
The image analysis method, by measuring bFGF levels in
individual tumors, provided values for each of the 87
tumors. In comparison, the visual examination results
provided readings of relative intensity which provided
only 4 scores (negative and three scores of positive stain-
ing). This, in turn, enabled the analysis of the relationship
between bFGF level and tumor sensitivity to the antipro-
liferation effect of paclitaxel in subgroups of tumors with
different pathobiological properties; the results show bet-
ter correlations in four pathobiological subgroups (late
stages, positive p53 staining, negative aFGF staining,
higher-than-median bFGF level), compared to all other
groups. These findings, in turn, improved our ability to
extract information and enabled the generation of the fol-
Table 1: Relationship between bFGF level and paclitaxel activity: Comparison of image analysis and visual scoring results. The linear 
regression relationships between bFGF levels and the antiproliferation effect of paclitaxel (measured as EMAX and IC30) were analyzed 
using SAS. p-values indicate probability associated with r2. The 95% confidence interval (95% CI) around r2 is approximated as 
described previously [22].
Antiproliferation effect of paclitaxel Relationship between bFGF level and chemosensitivity
r2 p-value 95% CI around r2
EMAX
Image Analysis 0.208 < 0.0001 0.074–0.370 §
Visual scoring 0.094 < 0.0001 0.011–0.236 §
IC30
Image Analysis 0.317 < 0.0001 0.160–0.478*
Visual scoring 0.084 < 0.01 0.007–0.222*
§ The r2 for image analysis showed a trend of being higher than the r2 for pathological scoring (p = 0.11).
* The r2 for image analysis (0.317) were outside the 95% CI for pathological scoring (0.007–0.222), indicating a statistically significant improvement 
in correlation using image analysis (p < 0.05).Journal of Translational Medicine 2008, 6:4 http://www.translational-medicine.com/content/6/1/4
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bFGF levels vs. paclitaxel effects (EMAX) in tumor subgroups Figure 3
bFGF levels vs. paclitaxel effects (EMAX) in tumor subgroups. (A) Complete data set (n = 87), (B) tumors with negative 
aFGF staining (n = 44), (C) tumors with positive aFGF staining (n = 43), (D) tumors with negative p53 staining (n = 54), (E) 
tumors with positive p53 staining (n = 33), (F) low stage tumors (stage I or II, n = 39), (G) high stage tumors (stage III or IV, n 
= 48), (H) tumors with bFGF levels less than or equal to the median value of 9.8 pg/mg protein (n = 44), and (I) tumors with 
bFGF levels greater than the median value (n = 43). Note the different x-axis in panel H (ranged from 0 to 10 pg/mg protein) 
compared to all other panels (ranged from 0 to 200 pg/mg protein). The r2 and p values for the correlations within each group 
are provided. The differences between the r2 values between each pair of subgroups (e.g., B vs C, D vs E, F vs G, H vs I) were 
significant (p < 0.05). The differences between the r2 values between the four subgroups with the high r2 values (i.e., negative 
aFGF, high stage, positive p53 staining, higher-than-median bFGF levels) and all 87 tumors were also significant (p < 0.05).
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bFGF levels vs. paclitaxel effects (IC30) in tumor subgroups Figure 4
bFGF levels vs. paclitaxel effects (IC30) in tumor subgroups. (A) complete data set (n = 87), (B) tumors with negative 
aFGF staining (n = 44), (C) tumors with positive aFGF staining (n = 43), (D) tumors with negative p53 staining (n = 54), (E) 
tumors with positive p53 staining (n = 33), (F) low stage tumors (stage I or II, n = 39), (G) high stage tumors (stage III or IV, n 
= 48), (H) tumors with bFGF levels less than or equal to the median value of 9.8 pg/mg (n = 44), and (I) tumors with bFGF lev-
els greater than the median value (n = 43). Note the different x-axis in panel H (ranged from 0 to 10 pg/mg protein) compared 
to all other panels (ranged from 0 to 200 pg/mg protein). The r2 and p values for the correlations within each group are pro-
vided. The differences between the r2 values between each pair of subgroups (e.g., B vs C, D vs E, F vs G, H vs I) were signifi-
cant (p < 0.05). The differences between the r2 values between the four subgroups with the high r2 values (i.e., negative aFGF, 
high stage, positive p53 staining, higher-than-median bFGF levels) and all 87 tumors were also significant (p < 0.05).
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lowing hypotheses. As p53 immunostaining is generally
accepted as indicative of mutated p53 [23] and high stage
tumors are generally more aggressive compared to low
stage tumors, we propose that the effects of bFGF on pacl-
itaxel resistance are more pronounced in the more aggres-
sive tumors with p53 mutation, or, alternatively, the bFGF
effects are masked by the presence of functional, wild type
p53. The finding of the apparently better correlation of
bFGF level and chemosensitivity in aFGF-negative tumors
was unexpected in view of our earlier finding that aFGF
amplifies the chemoresistance conferred by extracellular
bFGF, in cultured monolayer cells [24]. Multiple possible
reasons can explain this difference, including the micro-
environment and heterogeneity in human tumors com-
pared to cultured cells. Based on the better correlation in
the high bFGF-expressing tumors, we speculate that there
is a threshold bFGF level above which bFGF has a role in
chemoresistance.
Our finding of a lack of correlation between bFGF level
and the apoptotic effect of paclitaxel in patient tumors
suggests that bFGF level may not predict for tumor shrink-
age, a conventional method of measuring patient
response to chemotherapy. Finally, the current finding
that the relationship between intra-tumoral bFGF levels
and tumor sensitivity to the antiproliferation effect of
paclitaxel was dependent on the status of multiple tumor
pathobiological parameters suggests that the previous
contradictory findings on the merit of using plasma or
urine bFGF level as a prognostic indicator may be partly
due to heterogeneity in patient tumors.
Conclusion
The present study established a quantitative image analy-
sis method that enabled the measurement of intra-
tumoral bFGF level in archived tumor samples. The ability
to quantify a potential biomarker provided the opportu-
nity to study the relationship between the biomarker and
chemosensitivity in subgroups with different tumor
pathobiological parameters and thereby enabled further
hypothesis generation, a process that may have implica-
tions for translational research.
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